Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children
  ZIOPHARM Oncology is pleased to share a story from the Ann & Robert H. Lurie Children's Hospital in Chicago on the Ad-RTS-hIL-12 plus veledimex clinical trial for pediatric patients with brain cancer. As we announced last week, Stewart Goldman, M.D., Division Head Hematology-Oncology,
View HTML
Toggle Summary ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors
BOSTON, Oct. 16, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that the first patient has been dosed in a new Phase 1 study of Ad-RTS-hIL-12 with veledimex for the treatment
View HTML
Toggle Summary ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology
BOSTON, Oct. 12, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, today announced that three abstracts highlighting data from the Company's Ad-RTS-hIL-12 + veledimex program have been
View HTML
Toggle Summary ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer
BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focusing on new immunotherapies, announces the appointment of David Mauney, M.D., as Executive Vice President and Chief Business Officer, effective today.  ZIOPHARM also reports the details
View HTML
Toggle Summary ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting
BOSTON, Sept. 18, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that updated data from a subset of patients in its Phase 1 multicenter study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or
View HTML
Toggle Summary ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
BOSTON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Rodman & Renshaw 19 th Annual Global Investment Conference in New York on Tuesday, September 12, 2017 at 12:30 p.m. ET.
View HTML
Toggle Summary ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit
Data Highlighting the Non-viral Sleeping Beauty Gene Delivery System to Be Presented during Oral Session
View HTML
Toggle Summary ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities
Company to Host Conference Call Today at 4:30 p.m. ET
View HTML
Toggle Summary ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET
BOSTON, July 24, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday, July 31, 2017 at 4:30 p.m.
View HTML
Toggle Summary ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma
Stereotactic Study Arm Serves as Runway to Clinical Studies of Controlled IL-12 Gene Therapy in Pediatric Patients and in Combination with Checkpoint Inhibitors
View HTML